| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(9 years from now) | |
Zegalogue is owned by Zealand Pharma.
Zegalogue contains Dasiglucagon Hydrochloride.
Zegalogue has a total of 2 drug patents out of which 0 drug patents have expired.
Zegalogue was authorised for market use on 22 March, 2021.
Zegalogue is available in solution;subcutaneous dosage forms.
Zegalogue can be used as method of treating diabetic hypoglycemia.
Drug patent challenges can be filed against Zegalogue from 22 March, 2025.
The generics of Zegalogue are possible to be released after 03 February, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: Method of treating diabetic hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
ZEGALOGUE family patents
